Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis

Proceedings of the American Thoracic Society

Volumn 5, Issue 1, 2008, Pages 119-126

  Krymskaya, Vera P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Translational Research Laboratories   (United States)

Author keywords

Lung cancer; Mesenchymal cells; Signal transduction; TSC1; TSC2

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; S6 KINASE;

CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; ENZYME ACTIVITY; GENE CLUSTER; GENETIC DISORDER; HUMAN; LUNG PARENCHYMA; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; PROTEIN PHOSPHORYLATION; RARE DISEASE; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TSC1 GENE; TSC2 GENE; TUMOR SUPPRESSOR GENE; VASCULARIZATION;

CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MYOCYTES, SMOOTH MUSCLE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 37849033529     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200705-061VS     Document Type: Review

References (71)

1. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC.2 mutations: chromosome 16p13 loss of heterozygosity in angiolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998;62:810-815.
2. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000;97:6085-6090.
3. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis. J Biol Chem 2002;277:30958-30967.
4. Goncharova EA, Goncharov DA, Spaits M, Noonan D, Talovskaya E, Eszterhas A, Krymskaya VP. Abnormal smooth muscle cell growth in lymphangioleiomyomatosis (LAM): role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 2006;34:561-572.
5. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 2006;38:398-408.
6. Taveira-DaSilva AM, Moss J. Lymphangioleiomyomatosis. Cancer Control 2006;13:276-285.
7. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J 2006;27:1056-1065.
8. Goncharova EA, Krymskaya VP. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges. J Cell Biochem [E-pub ahead of print 31 May 2007].
9. Matsui K, Beasley MB, Nelson WK, Barnes PJ, Bechtle J, Falk R, Ferrans VJ, Moss J, Travis WD. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 2003;25:479-484.
10. Moss J, editor. LAM and other diseases characterized by smooth muscle proliferation. New York: Marcel Dekker; 1999. 663pp.
11. Travis WD, Usuki J, Horiba K, Ferrans VJ. Histopathological studies on lymphangioleiomyomatosis. In: Moss J, editor. LAM and other diseases characterized by smooth muscle proliferation. New York: Marcel Dekker; 1999. pp. 171-217.
12. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-1356.
13. Astrinidis A, Khare L, Carsillo T, Smolareck T, Au KS, Northrup H, Henske EP. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 2000;37:55-57.
14. Kwiatkowski DJ. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 2003;67:87-96.
15. Zhe X, Schuger L. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 2004;52:1537-1542.
16. Logginidou H, Ao X, Russo I, Henske EP. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest 2000;117:25-30.
17. Brentani MM, Carvalho CR, Saldiva PH, Pacheco MM, Oshima CT. Steroid receptors in pulmonary lymphangiomyomatosis. Chest 1984;85:96-99.
18. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang J-a, Kumaki F, Darling T, Moss J. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004;101:17462-17467.
19. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-982.
20. Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O. Mutational analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangileiomyomatosis. J Hum Genet 2002;47:20-28.
21. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006;34:473-480.
22. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 2001;164:1537-1540.
23. Herzog EL, Krause DS. Engraftment of marrow-derived epithelial cells: the role of fusion. Proc Am Thorac Soc 2006;3:691-695.
24. Giangreco A, Groot KR, Janes SM. Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med 2007;175:547-553.
25. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Migrating cancer stem cells: an integrated concept of malignant tumor progression. Nat Rev Cancer 2005;5:744-749.
26. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001;68:64-80.
27. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet 2005;13:731-741.
28. Wilson C, Bonnet C, Guy C, Idziaszczyk S, Colley J, Humphreys V, Maynard J, Sampson JR, Cheadle JP. Tsc1 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in tsc1+/- mice. Cancer Res 2006;66:7934-7938.
29. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet 2000;107:97-114.
30. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 2006;3:393-402.
31. Krymskaya VP. Tumor suppressors hamartin and tuberin: intracellular signaling. Cell Signal 2003;15:729-739.
32. Cai S-L, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL. Activity of TSC2 is inhibited by Akt-mediated phosphorylation and membrane partitioning. J Cell Biol 2006;173:279-289.
33. Chong-Kopera H, Inoki K, Li Y, Zhu T, Garcia-Gonzalo FR, Rosa JL, Guan K-L. Tsc1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem 2006;281:8313-8316.
34. Goncharova E, Goncharov D, Noonan D, Krymskaya VP. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the RAC1 GTPase. J Cell Biol 2004;167:1171-1182.
35. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, Onda H. A mouse model of tsc1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6K kinase activity in tsc1 null cells. Hum Mol Genet 2002;11:525-534.
36. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ. Loss of TSC1/TSC2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003;112:1223-1233.
37. Krymskaya VP, Shipley JM. Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol 2003;28:546-550.
38. Findlay GM, Harrington LS, Lamb RF. TSC1-2 tumor suppressor and regulation of mTOR signalling: linking cell growth and proliferation? Curr Opin Genet Dev 2005;15:69-76.
39. Lee C-H, Inoki K, Guan K-L. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 2007;47:443-467.
40. Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 2006;25:6361-6372.
41. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-430.
42. Inoki K, Ouyang H, Li Y, Guan K-L. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 2005;69:79-100.
43. Inoki K, Corradetti MN, Guan K-L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37:19-24.
44. Nobukini T, Thomas G. The mTOR/S6K signaling pathway: the role of the TSC1/2 tumor suppressor complex and the proto-oncogene Rheb. Novartis Found Symp 2005;262:148-159.
45. Vivekanand P, Rebay I. Intersection of signal transduction pathways and development. Annu Rev Genet 2006;40:139-157.
46. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by ERK: implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-193.
47. Han S, Santos TM, Puga A, Roy J, Thiele EA, McCollin M, Stemmer-Rachamimov A, Ramesh V. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res 2004;64:812-816.
48. Gan B, Yoo Y, Guan J-L. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of S6 kinase activation and cell growth. J Biol Chem 2006;281:37321-37329.
49. Gan B, Melkoumian ZK, Wu X, Guan K-L, Guan J-L. Identification of FIP200 interaction with the TSC1-TSC2 complex and its role in regulation of cell size control. J Cell Biol 2005;170:379-389.
50. Gan B, Peng X, Nagy T, Alcaraz A, Gu H, Guan J-L. Role of fip200 in cardiac and liver development and its regulation of TNFα and TSC-mTOR signaling pathways. J Cell Biol 2006;175:121-133.
51. Hsu Y-C, Chern JJ, Cai Y, Liu M, Choi K-W. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 2007;445:785-788.
52. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-734.
53. Polak P, Hall MN. mTORC2 caught in a sinful Akt. Dev Cell 2006;11:433-434.
54. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502.
55. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. Ablation in mice of the mTORC components raptor, rictor, or MLST8 reveals that mTORC2 is required for signaling to Akt-Foxo and PKCα, but not S6K1. Dev Cell 2006;11:859-871.
56. Yang Q, Inoki K, Ikenoue T, Guan K-L. Identification of SIN1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 2006;20:2820-2832.
57. Shiota C, Woo J-T, Lindner J, Shelton KD, Magnuson MA. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 2006;11:583-589.
58. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006;127:125-137.
59. Guertin DA, Guntur KVP, Bell GW, Thoreen CC, Sabatini DM. Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol 2006;16:958-970.
60. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101.
61. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007;47:185-210.
62. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006;126:955-968.
63. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006;127:469-480.
64. Choo AY, Roux PP, Blenis J. Mind the gap: Wnt steps onto the mTORC1 train. Cell 2006;126:834-836.
65. Ellisen LW. Growth control under stress. Cell Cycle 2005;4:e58-e60.
66. Corradetti MN, Inoki K, Guan K-L. The stress-inducted proteins RTP801 and RTP801l are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 2005;280:9769-9772.
67. Reiling JH, Hafen E. The hypoxia-induced paralogs scylla and charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev 2004;18:2879-2892.
68. Goncharova EA, Goncharov DA, Krymskaya VP. Assays for in vitro monitoring of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cell migration. Nat Protocols 2006;1:2933-2939.
69. Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, Hall A. The TSC1 tumor suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase rho. Nat Cell Biol 2000;2:281-287.
70. Goncharova EA, Goncharov DA, Lim PN, Krymskaya VP. Simvastatin modulates rhoa activity, proliferation and migration of LAM-derived cells. Am J Respir Crit Care Med 2007;175:A345.
71. Goncharova EA, Lin P, Goncharov DA, Eszterhas A, Panettieri RA Jr, Krymskaya VP. Assays for in vitro monitoring proliferation of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cells. Nat Protocols 2006;1:2905-2908.